Cannaccord Genuity Asserts Hold Stance on Caris Life Sciences, Inc. (CAI) On Oncology Pipeline Development

Caris Life Sciences Inc. (NASDAQ:CAI) is one of the best biotech stocks to buy according to Wall Street analysts. On December 4, 2025, Caris Life Sciences (NASDAQ:CAI) announced it will present 19 breast cancer studies at the San Antonio Breast Cancer Symposium, conducted with more than 40 partner institutions through the Caris Precision Oncology Alliance. Spanning seven disease subtypes, the work showcases how Caris’ multi-omic tumor profiling, AI-driven signatures, and biomarker discovery improve recurrence prediction, risk stratification, and outcomes. Executives highlighted the company’s leadership in integrating exome and transcriptome sequencing with IHC profiling, with two studies chosen for oral presentation underscoring its advances in personalized cancer care.

Cannaccord Genuity Asserts Hold Stance on Caris Life Sciences, Inc. (CAI) On Oncology Pipeline Development

Tonhom1009/Shutterstock.com

Earlier on December 2, analysts at Cannaccord Genuity initiated coverage of the stock with a Hold rating and a $28 price target. The company remains in a strong position in the precision oncology market, owing to its differentiated multi-modal platform and early momentum in tissue and blood-based therapy selection.

Likewise, the company’s dual-modality infrastructure and robust data assets also affirm its prospects in oncology, backed by an expanding artificial intelligence suite. Consequently, the company posted a 113% increase in Q3 revenue to $216.8 million. It also posted a positive adjusted EBITDA of $51.2 million, affirming improved operational efficiency.

Caris Life Sciences, Inc. (NASDAQ:CAI) is a precision medicine company focused on oncology that offers advanced tumor profiling to help doctors personalize cancer treatment by analyzing a tumor’s unique molecular signature to guide therapy, find clinical trials, and predict drug effectiveness.

While we acknowledge the potential of Caris Life Sciences, Inc. (NASDAQ:CAI) as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than CAI and that has 100x upside potential, check out our report about the cheapest AI stock.

READ NEXT: 12 Best Consumer Goods Stocks Billionaires Are Quietly Buying and Goldman Sachs Penny Stocks: Top 12 Stock Picks.

Disclosure: None. This article is originally published at Insider Monkey.